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Introduction
Immune system operates as a surveillance and de-
fense system of the animal body. It is programmed
to work for the good will of the body by fighting
both intracellular as well as extracellular foreign
pathogens. Immune system seldom acts abnor-
mally against the individual’s body which might
culminate in deleterious consequences. An individ-
ual can concede immune mediated disease either
by the failure of immune-regulation or by mount-
ing an abnormal immune response against the self
body components. An abnormal consequence of
the immune functions for instance autoimmunity,
hypersensitivity, immunodeficiency, immunosup-
pression or any combination of these may culmi-
nate in immune mediated diseases (Tizard, 2009).
Immune mediated musculoskeletal diseases are
major ailments caused by immune system dysfunc-
tion which are responsible for abnormalities of
skeleton and ambulation. They have complex clin-
ical presentation which makes diagnosis a chal-
lenging task. The article aims to review the clinical
pattern, advances in diagnostics and management
of important immune mediated musculoskeletal
diseases occurring commonly in dogs.
Immune mediated musculoskeletal diseases 
Immune mediated arthritides/polyarthritis
Immune mediated arthritis is comprised of a group
of inflammatory but non-infectious affections of
joints which responds to immunosuppressive ther-
apy (Kohn, 2007). Inflammation is either due to
persistence of an antigenic material in the syn-
ovium of affected joints, possibly as sequel to pre-
vious infection, or to deposition of immune
complexes in synovium, derived from inflamma-
tory lesions elsewhere in the body. Immune medi-
ated arthritis is typically a polyarthritis involving
more than one joint. It is common in dogs and cats
and is characterized by the major involvement of
joints of locomotion. Idiopathic polyarthritis, sys-
temic lupus erythematous (SLE) associated pol-
yarthritis, drug induced polyarthritis, polyarthritis
of Grey hounds, rheumatoid arthritis are some of
the examples of polyarthritis most commonly re-
ported in dogs (Thompson, 2005, Day and Bennett,
2008). Immune mediated arthritides has been cat-
egorized in to erosive and non-erosive arthritis
based on radiographic changes observed in joints
and bone (Bennett, 2005).
1. Erosive arthritis: 
Erosive arthritis constitutes immunological process
that occurs in the joint itself with acceleration of
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pannus formation ultimately terminating in devel-
opment of erosions of the margins of articular car-
tilage, instability or luxation of joints, or fusion of
low-motion joints.  Rheumatoid arthritis and Pol-
yarthritis of Grey Hounds are important erosive
arthritides frequently reported in dogs.
1. a. Rheumatoid arthritis (R.A.)
It is the most common type of canine erosive pol-
yarthritis which typically affects small & toy
breeds irrespective of sex & age (Tizard, 2009). It
is a potentially deforming & crippling idiopathic,
symmetrical polyarthritis of dogs & cats basically
similar to human counterpart. It is mostly prevalent
in small and toy breeds of dogs with no sex or age
predilection (Thompson, 2005). Clinically disease
is characterized by episodes of anorexia, depres-
sion & fever with generalized or shifting lameness
associated with development of swelling around af-
fected joints and eventual erosive changes in joints.
It has progressive course with involvement of mul-
tiple joints (tarsal, carpal & phalangeal joints) in
advanced stage of the disease which are persist-
ently swollen & painful. Progression of disease
eventually results in destruction of articular carti-
lage & bone. With progression of inflammation
there is swelling and proliferation of synovia with
outgrowths of fibrous vascular tissues (pannus) ex-
tending into the joint cavities. Protease released
from panuus produces ‘punched out’ erosions of ar-
ticular cartilage and destruction of adjacent bones
(Bennett, 1987a). Radiography reveals soft tissue
swellings followed by loss of bone density, col-
lapse of the joint space, joint luxation, fibrous or
bony ankylosis in advanced disease.
Various infectious agents have been implicated
for R.A. but none have direct involvement. Indirect
involvements through generation of immune com-
plexes or induction of autoimmunity by molecular
mimicry are possible mechanisms (Thompson,
2005). Irrespective of etiology, the deposition of
immune complexes in articular structures is central
to the pathology followed by complement activa-
tion terminating in joint tissue injury. The autoanti-
gen involved in R.A. is still not well defined but
three major autoantigens, viz., Rheumatoid Factor
(RF), collagen and glycosaminoglycans may be
implicated in the development of disease (Thomp-
son, 2005). Rheumatoid Factors are the autoanti-
bodies of IgM, IgG and IgA subclass directed
against altered host IgG (Tizard, 2009). These can
be detected in synovial fluid & sometimes in serum
of the affected dogs. RF’s can be also detected in
dogs with systemic lupus erythematosus (SLE) and
other diseases involving extensive immune com-
plex generation. Serum anti-type II collagen anti-
bodies determined by ELISA have been
demonstrated in R.A. positive dogs with correla-
tion between levels of anti-collagen type II anti-
bodies and total IgG in the immune complexes
(Bari et al., 1989). Antigens of canine distemper
have been demonstrated in synovial fluid of dogs
with R.A. which suggest possible role of natural in-
fection or vaccination in R.A. (Bell et al., 1991).
The diagnostic criteria’s for R.A. in dog are
adapted from those defined for human by American
Rheumatism Association (Thompson, 2005, Day
and Bennett, 2008). In dogs these includes, stiff-
ness, pain on manipulation of at least one joint,
signs of arthritis for at least 3 months, periarticular
soft tissue swelling, typical radiographic changes,
subchondral bone destruction, irregularity of the ar-
ticular surface or punched out erosions, deminer-
alization of the epiphysis, calcification of soft
tissue around joint, changes in joint space, finally
extensive bone destruction with gross joint defor-
mity, inflammatory synovial fluid, characteristic
symmetrical deformations of the distal joints, de-
tection of rheumatoid factor in serum, characteris-
tic histopathological changes in synovial
membrane, and extra articular symptoms (ten-
dosynovitis, lymphadenopathy). The presence of at
least 5 of above criteria suggests disease while dogs
positive for 7 or more criteria are declared positive
for rheumatoid arthritis. Radiography and detection
of RF in synovial fluid or sometimes in serum is
also helpful in diagnosis (Bennett, 2005). The syn-
ovial effusion contains large number of polymor-
phonuclear cells and there is massive infiltration of
lymphocytes in synovial membrane with formation
of germinal centers (Bennett, 1987a, b, Newton et
al., 1976). Increased levels of matrix metallopro-
teinases 9 with high gelatinolytic activity in syn-
ovial fluid has been reported in dogs with R.A. but
its significance in non-erosive arthritis is still un-
known (Coughlan et al., 1998).
Treatment commonly started with Non Steroidal
Anti-inflammatory Drugs (NSAIDs) & antibiotic
particularly Doxycycline until the availability of
confirmative diagnosis (Kohn, 2007). Treatment of
R.A. with drugs is likely to be disappointing and
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disease carries poor prognosis (Day and Bennett,
2008). After ruling out infectious etiology & diag-
nostic confirmation of disease, treatment should be
sidetracked to immunosuppressive drugs like cor-
ticosteroids e.g. Prednisone, Prednisolone at 2-4
mg/kg PO orally in divided doses for at least 2
weeks with gradual tapering of the dose over next
6-8 weeks with improvement in clinical signs. But
use of corticosteroids is controversial as it delays
healing and known to promote articular degenera-
tion (Gorman and Werner, 1986b).  If corticosteroid
treatment fails to contain relapse then regimen
should be shifted to cytotoxic drugs like Cy-
clophosphamide at 1.5-2.5 mg/kg orally for 4 con-
secutive days every week for 2-4 months with low
dose prednisolone (0.25-0.5 mg/kg) daily to control
pain. Prolonged therapy with cyclophosphamide
causes sterile hemorrhagic cystitis as well as bone
marrow suppression, so monitoring of hematolog-
ical parameters as well as regular examination of
urine at interval of 7-14 days should be done to rule
out drug toxicity (Peterson et al., 1992; Day and
Bennett, 2008). Use of gold preparations
(chrysotherapy)  which have been categorized as
slow-acting anti-rheumatic drugs (SAARD) like
aurothiomalate and auranofine has been limited by
high cost and adverse effects on different organ
systems (Kohn, 2007, Day and Bennett, 2008).
Surgical arthrodesis has been indicated in advanced
cases of R.A. to restore the joint mobility (Gorman
and Werner, 1986b). In human cases of R.A. im-
munomodulatory therapies that either induce or
block cytokines have been used like monoclonal
antibodies to TNF-α (Infliximab), CD4, thymo-
cytes or IL-2R have shown significant anti-inflam-
matory activity along with inhibition of matrix
metalloproteinase production (Ferraro-Peyret et al.,
2004, Chung et al., 2007). But these anti-cytokine
therapies are not developed for canine R.A to the
date. 
1. b. Polyarthritis of Greyhounds
An erosive polyarthritis has been described in
Greyhounds in Australia, U.K. and USA. It affects
both sexes and characterized by mild to severe
lameness, joint swelling affecting the gait due to
involvement of limb joints (Thompson, 2005). No
infectious agent has been confirmed yet for pol-
yarthritis of Greyhounds. It causes a non-suppura-
tive inflammation of synovium frequently with
concurrent destruction of articular cartilage in limb
joints (Huxtable and Davis, 1976). 
2. Non-erosive arthritis: 
The primary disease is located somewhere else in
the body and products of immune process are de-
livered to the capillary bed of synovium of affected
joints. Here the primary disease may be transient,
cyclic, or responsive to treatment, and is not cen-
tered in joint. So, the products of immune response
that initiates the synovitis can be cleared periodi-
cally or permanently from joint. Thus, there is no
chronic stimulation of pannus or destruction of ar-
ticular surfaces (Gorman and Werner, 1986b,
Thompson, 2005). Non-erosive arthritis includes
idiopathic polyarthritis, drug-induced arthritis, pol-
yarthritis/polymyositis syndrome, lymphocytic
/plasmacytic arthritis and Systemic Lupus Erythe-
matosus (SLE).
2. a. Idiopathic polyarthritis (IPA)
It is by far the most common of all the immune-
mediated arthropathies in dog. The “idiopathic”
type is again categorized into 4 subcategories (Ben-
nett, 1987c, Bennett, 2005, Kohn 2007). Type I
(uncomplicated) IPA accounts for approximately
50% of all the “idiopathic” cases in which under-
lying disease or trigger usually untraceable. Type
II (reactive) IPA is associated with infectious dis-
ease outside the joints which might provide a
source of antigen for immune mediated injury (ap-
proximately 25% of all IPA cases). Infections of the
respiratory tract, urogenital tract, teeth, ears or skin,
leishmaniasis, ehrlichiosis, anaplasmosis, borrelio-
sis, and bacterial endocarditis have been reported
to have association with type II IPA (Roush et al.,
1989, Thilagar et al., 1990, Spreng, 1993). Type III
(enteropathic/hepatopathic) IPA is associated with
gastrointestinal diseases. The diseased gut may
cause increase in permeability to potential antigens
which might stimulate the production of immune
complexes. Type IV (paraneoplastic) IPA occurs in
association with neoplasia outside the joints, e.g.
squamous cell carcinoma, leiomyoma, mammary
carcinoma, and lymphoma. Formation of circulat-
ing immune complexes might occur by activation
of immune system by neoplastic conditions.
Weight of evidence suggests that the synovitis is
secondary to deposition of circulating immune
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complexes in the synovial capillary bed (Bennett,
1987c, Kohn, 2007).
An immune-based polyarthritis can follow vac-
cinations, either after the first injection or after
booster vaccinations have been reported in dogs
(Bell, et al., 1991). The lameness is often only tran-
sient, lasting for several days. More severe form
has been described in Weimaraner and Akita Inu
puppies up on vaccination with modified live ca-
nine distemper vaccine (Day and Bennett, 2008).
IPA generally affects male dogs with around half
of the cases in young dogs in the age group of 1-
3.5 years (Tizard, 2009). Disease is characterized
by overt lameness or stiffness after rest or exercise,
stiff gait, reluctance to move, lethargy, inappetance,
fever, and shifting leg lameness. The disease is di-
agnosed by examination of synovial fluid. The
changes like increase in volume, turbidity, discol-
oration, decreased viscosity and clot formation are
detected in synovial fluid from affected joints.
Total protein and nucleated cell count also used to
incline towards higher side. 
Treatment starts with analgesics like Meloxicam
at 0.1 mg/kg or Carprofen at 2-4 mg/kg are used to
control pain, fever and inflammation in type I IPA
or vaccine induced arthritis.  Immunosuppressive
therapy is initiated with corticosteroids (Pred-
nisolone at 2-4 mg/kg q24hr for 2 weeks with grad-
ual tapering of dose with clinical improvement over
next 3-4 months). Dogs respond well to corticos-
teroid treatment with better prognosis than other
forms of immune arthritis (Tizard, 2009). Always
avoid simultaneous use of glucocorticoids and
NSAIDs which might end in life threatening gas-
trointestinal ulceration (Kohn, 2007, Bolten, 2010).
If there is no improvement in signs, cytotoxic drugs
like cyclophosphamide at1.5 mg/kg (dogs with >
30 kg BW), 2 mg/kg (dogs with 15-30 kg BW) and
2.5 mg/kg (dogs with <15 kg BW) every four con-
secutive days per week for 3-4 months with low
dose prednisolone (0.25-0.5 mg/kg po q24hr) is
successful regimen (Kohn, 2007). Azathioprine at
2 mg/kg with low dose prednisolone could be used
both on alternate days with regular hematological
monitoring.
2. b. Drug induced arthritis
Drug induced arthritis is also considered to be im-
mune mediated which is observed in a small pro-
portion of dogs. Dobermans are generally more
susceptible when treated with potentiated sulfon-
amides (Sulfadiazine-Trimethoprim) are usually re-
sponsible through development of drug-antibody
complex leading to type III hypersensitivity medi-
ated injury (Little and Carmichael, 1990, Cribb,
1989). The drugs may act directly as an antigen or
as a hapten in combination with host proteins. The
disease is clinically characterized by polyarthritis,
fever, and occasionally lymphadenopathy, anemia,
leukopenia, and thrombocytopenia which develop
after 8-20 days of treatment with predisposed drugs
(Thompson, 2005). Most common drugs responsi-
ble for drug induced arthritis include antimicrobials
like lincomycin, erythromycin, penicillin’s,
cephalosporins, and sulfonamides (Kohn, 2007).
Diagnosis is based on the worsening of the symp-
toms up on continuation of therapy. Line of treat-
ment includes immediate withdrawal of
responsible drug. Clinical signs usually regress
within 2-5 days of drug withdrawal. Immunosup-
pressive doses of corticosteroids like prednisolone
(1-2 mg/kg PO q24hr) could be used (Day and
Bennett, 2008).
2. c. Polyarthritis/Polymyositis syndrome
Polyarthritis/Polymyositis is most prevalent in
Spaniel breed and is clinically characterized by de-
velopment of marked stiffness, poor exercise tol-
erance with crouched stance, muscle swelling and
pain in the early stages of disease (Bennett and
Kelly, 1987). There might be atrophy of muscle
with contracture leading to reduced mobility of
joints in affected areas. Serum biochemistry illus-
trates increased levels of muscle enzymes like Cre-
atinine Kinase (CK), Aspartate Aminotransferase
(AST) and Aldolase (Day and Bennett, 2008). For
diagnosis of disease, muscle biopsy from at least 6
different areas should be taken for histopathology,
of which at least two samples should be positive
for inflammatory changes. Aggressive therapy with
cytotoxic drugs (cyclophosphamide, azathioprine,
and cyclosporine) is preferred to control the disease
in combination with low dose prednisolone. The
syndrome can also be treated with prednisolone at
1-2 mg/kg PO q 24 hours till improvement in the
clinical signs followed by gradual tapering of dose
over next 2-3 months.
2. d. Lymphocytic/Plasmacytic arthritis
It is an insidious syndrome affecting mainly
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small to medium size dogs with propensity for sti-
fle joint. The disease may be accompanied by joint
laxity, partial or complete rupture of cranial cruci-
ate ligament without any order in occurrence of le-
sions. The probable etiology of might be an
exaggerated immune response to mediators or anti-
gens released following ligament damage, surgical
correction or as a result of an ensuing degenerative
joint disease (Thompson, 2005). Grossly synovial
membrane shows edematous thickening with
red/yellow discoloration. Microscopic examination
is characterized by marked diffuse and/or nodular
infiltration of plasma cells or lymphocytes in the
synovium and hypertrophy of synovial cells.
Mononuclear cell infiltration (lymphocytes and
plasma cells) is also reported in the synovial fluid.
There is no clear cut evidence to show the immuno-
logical cause as a primary etiological agent in the
disease (Day and Bennett, 2008). Management of
disease is done with immunosuppressive doses of
prednisolone.
2. e. Systemic Lupus Erythematosus (SLE)
It is a basically polysystemic autoimmune disorder
of human, and also prevalent in other primates,
horses, dogs, cats and laboratory animals. How-
ever, polyarthritis is the most consistent clinical
finding of SLE in dogs and is the most cited exam-
ple of non-erosive polyarthritis in canines (Day and
Bennett, 2008). Male dogs are more predisposed to
SLE with Collies, Shetland Sheepdogs, German
shepherd dogs being most commonly affected
breeds. It is a classical example of failed im-
munoregulation (Tizard, 2009). The imbalances in
populations of T-cell subsets results in B cell hy-
peractivity through altered immunoregulation lead-
ing to general failure of immune system
culminating in the production of antibodies against
variety of membrane and soluble antigens like, an-
tinuclear antibodies (dsDNA, histones), extractable
nuclear antigens (Sm, RNP) and anti-phospholipids
antibodies (Tizard, 2009). These auto antibodies
are responsible for type III hypersensitivity medi-
ated organ-specific and non-organ specific dam-
ages through immune complex medicated injury
(Ginn et al., 2005).
The exact cause of SLE is not clear. However,
most researchers cite a combination of predispos-
ing factors including genetic, environmental, drug
induced, hormonal, and viral influences, that alter
suppressor T cell function allowing the expansion
of autoreactive Th cell (helper T cell) and B cell
clones with the production of auto-antibodies (Gor-
man and Werner, 1986a).
Clinical signs of the disease are categorized in
two classes based on frequency of occurrence, viz.,
Major and minor signs which are as follows (Gor-
man and Werner, 1986a), 
Neither major nor minor signs are truly specific
for SLE. Rather a combination of these signs to-
gether with serological tests establishes disease di-
agnosis. 
Classic SLE:
The diagnosis applies to cases presenting with two
major signs and positive serological evidence or
with one major and two minor signs together with
positive serology.
Probable SLE: 
If one major sign is present with positive serology
or when two major signs are present without posi-
tive serology. 
Fournel et al. (1992) studied 75 cases of SLE
positive dogs and reported polyarthritis as a most
common clinical finding followed by renal, muco-
cutaneous disorders and hemolytic anemia with
greater predisposition of male German shepherd
dogs. Central to diagnosis of SLE is demonstration
of significant titers of antinuclear antibody (ANA)
by indirect immunofluorescence and lupus cell test
(Fournel et al., 1992, Day and Bennett, 2008).  
The prognosis of SLE is guarded due to multi-
systemic involvement, so needs institution of ag-
gressive immunosuppressive therapy. Supportive
care along with tapering doses of glucocorticoids
alone or with cytotoxic drugs is the general line of
treatment. Combination therapy using prednisolone
and azathioprine has proved to be effective in re-
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Major signs Minor signs
Polyarthritis
Proteinuria (Glomeru-
lonephritis)
Dermatosis
Anemia (Coombs posi-
tive)
Leukopenia
Thrombocytopenia
Fever
Pleuritis
Oral ulcers
Neurological disease
Myocarditis/Pericardi-
tis
Lymphadenopathy
fractory cases or cases in which the maintenance
dose of prednisolone produces unacceptable side
effects (Stone, 2005). Induction doses of pred-
nisolone at 2-4 mg/kg should be used reducing to
an every other day maintenance dose of 0.5-1
mg/kg. Azathioprine can be given at 1-2 mg/kg
daily reducing to 1 mg/kg every other day (pred-
nisolone can be given on alternate days to the aza-
thioprine). Novel therapeutic combination of
prednisolone at 1-2 mg/kg daily orally (for 2
months) along with Levamisole at 2-5 mg/kg orally
every alternate day continued for 4 months have
shown encouraging recovery in dogs (Stone, 2005,
Fournel et al., 1992). In face of relapse only lev-
amisole therapy should be repeated for four more
months (Day, 2008, Chabanne et al., 1995). An at-
tempt to stop therapy may be made in dogs remain-
ing disease free for six months. The most common
causes of death in SLE patients are renal failure and
infections like bronchopneumonia and septicemia.
Immune mediated muscular diseases
a) Myasthenia gravis
It may be either acquired or congenital disorder re-
ported in human, dogs and cats. Disease is charac-
terized by ineffective neuromuscular transmission
secondary to the reduction in nicotinic acetyl
choline (ACh) receptors on postsynaptic muscle
membrane (acquired) or from genetical, structural
or functional abnormalities of ACh receptors (con-
genital). In acquired form auto antibodies usually,
IgG are generated against ACh receptors which
blocks neuromuscular transmission either by di-
rectly interfering with the action of ACh on recep-
tors or activation of compliment mediated lysis of
post-synaptic membrane (Drachman, 1994, Dewey
et al., 1997). Congenital form which occurs due to
an inherited deficiency of these Ach receptors is
common in Jack Russell Terriers, Springer
Spaniels, and Fox Terriers (Couturier et al., 2009).
Myasthenia gravis involves spectrum of clinical
signs and disease has been classified in to three
types, viz., focal, chronic generalized and acute ful-
minant generalized myasthenia (Dewey et al.,
1997). Focal form is characterized by variable de-
gree of facial, pharyngeal, laryngeal and
esophageal dysfunction. Chronic generalized form,
and acute fulminant generalized forms distin-
guished primarily by the rate with which clinical
signs develop. Dogs have generalized muscular
weakness which worsens with exercise, non-ambu-
latory tetraparesis, and severe dyspnea. Megae-
sophagus is common in all forms of disease which
is responsible for chronic regurgitation and aspira-
tion pneumonia (Shelton et al., 1990, Webb et al.,
1997). Diagnosis is based on history and clinical
signs. Confirmatory diagnosis requires demonstra-
tion of serum antibodies that reacts with alpha bun-
garotoxin extracted ACh receptors in muscles by
immunoprecipitation or radioimmunoassay. Test is
highly sensitive and specific for autoimmune
myasthenia gravis (Shelton, 2002). Also there is in-
crease in strength of muscle after administration of
short acting anti-cholinesterase like edrophonium
chloride (Tensilon). Antibodies have also been de-
tected to muscle protein ‘titin’ and Ca2+ channel
receptor ‘raynodine (RyR)’ (Tizard, 2009). Canine
nicotinic ACh receptor alpha subunit gene has been
cloned successfully and ELISA has been developed
to diagnose dogs with antibodies to these receptors
(Yoshioka et al., 1999). 
The disease can be managed on long term anti-
cholinesterase therapy in order to prolong the in-
teraction of ACh with receptors. Pyridostigmine
bromide at 1-3 mg/kg q 8-12 hr or Neostigmine at
0.04 mg/kg IM q 6hr can be given to myasthenic
dogs. But these treatments have minimal effect on
esophageal motility. Shelton and Lindstrom (2001)
treated 53 dogs diagnosed positive for autoimmune
canine myasthenia gravis with anticholiesterase
therapy only and reported clinical and immunolog-
ical remission in 47 dogs within an average period
of 6.4 month. Corticosteroid therapy started with
lower dose and gradually increased dose has been
reported to manage disease in some cases (Maddi-
son et al., 1984).
b) Masticatory muscle myositis (MMM)
It is an immune mediated inflammatory disorder
selectively affecting the muscles of mastication in
canines. The common muscles involved are mas-
seter, temporalis and pterygoid muscles. It’s basis
as immune mediated disease has been confirmed
by detection of auto antibodies against 2M myosin
muscle fibers which is unique isoform of myosin
primarily present in massetor muscles of dogs
(Shelton et al., 1987), as well as infiltration of
mononuclear cells and clinical response to im-
munosuppressive therapy (Van Vleet and Valen-
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tine, 2005, Taylor, 2000). Syndrome of masticatory
muscle myositis is common in large breed dogs like
German shepherd, Cavalier King Charles Spaniels
with bilaterally symmetrical involvement of mus-
cle.  Both acute and chronic forms of MMM have
been described in dogs (Lewis, 1994). Acute form
is characterized by swelling of masticatory muscles
with myalgia, reluctance to open mouth, difficulty
in eating and drooling of saliva (Clooten et al.,
2003). Swelling of muscles may results in exoph-
thalamos, terminating in keratitis and conjunctivitis
(Brogdon et al., 1991). Mostly MMM occurs as
chronic condition which leads to severe progressive
muscle atrophy and affected dogs are unable to
open mouth fully. Masticatory muscle myositis is
progressive disease and affected dogs may develop
aspiration pneumonia or complications of corticos-
teroid therapy leading to death. 
Masticatory muscle myositis is diagnosed on
the basis of clinicopathological abnormalities like
myalgia, difficulty in opening the jaw, increased
serum creatine kinase (CK), leukocytosis with neu-
trophilia and occasionally lymphocytes or
eosinophils. But these findings being non-specific,
confirmatory diagnosis is based on demonstration
of antibodies against type 2M muscle fibers in
muscle biopsy as well as histopathological findings
like inflammatory or degenerative lesions (necrosis
and phagocytosis of 2M fibers with infiltration of
lymphocytes and plasma cells) affecting the M2
myofibrils (Van Vleet and Valentine, 2005).
Corticosteroids are commonly used to treat the
MMM in dogs with prednisolone at 1-2 mg/kg BW
orally twice a day with gradual reduction in the
dose rate up on clinical remission. Cytotoxic drugs
like azathioprine might be required in dogs unre-
sponsive to prednisolone therapy. To avoid the side
effects like muscle weakness by corticosteroid ther-
apy, doses of prednisolone should be gradually in-
creased for effective therapy (Shelton, 2002). The
disease is having good prognosis if treated prop-
erly, but relapses may occur (Taylor, 2000, Lewis,
1994).
c) Polymyositis
It is a generalized autoimmune myositis that occurs
most commonly in adult dogs of large breeds like
German Shepherds (Tizard, 2009) and is presented
with variable signs like progressive muscle weak-
ness not associated with exercise, changes in laryn-
geal muscle function leading to change in the
voice, and shifting leg lameness. Megaesophagus
may lead to dysphagia and, if severe, can result in
regurgitation and aspiration pneumonia (Presthus
and Lindboe, 1988). Animals may be febrile and
develop leukocytosis and eosinophilia. The disease
may be acute or gradual in onset with primary sign
relating to involvement of masticatory muscles, so
both MMM and polymyositis needs to be consid-
ered for confirmatory diagnosis (Van Vleet and
Valentine, 2005). The syndrome of polymyositis
may be accompanied by the variety of diseases like
SLE (Krum et al., 1977). Pathological changes in-
clude degenerative changes in muscle fibers, necro-
sis, vacuolation and affected muscles may be
infiltrated by lymphocytes and plasma cells. Serum
biochemistry shows an increase in serum levels of
muscle enzymes like Creatinine Kinase (CK), As-
partate Aminotransferase (AST) and Aldolase
(Gorman and Werner, 1986a, Presthus and Lind-
boe, 1988). Immunophenotyping revealed that the
lymphocytes that invade affected muscles are
mainly of cytotoxic (CD8+) type (Neumann and
Bilzer, 2006). Corticosteroid therapy is effective in
most cases (prednisolone at 0.5-1 mg/kg PO
q24hr), but care should be taken to rule out infec-
tious causes like toxoplasmosis, fungal and bacte-
rial infections before initiation of therapy.
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